ibandronatehttp://www.unboundmedicine.com/medline/ebm/research/ibandronateUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Safety and antisorptive power of Ibandronate applied in the real-life setting.http://www.unboundmedicine.com/medline/ebm/record/19894333/full_citation/Safety_and_antisorptive_power_of_Ibandronate_applied_in_the_real_life_setting_Bunyaratavej N, Wajanavisit W, Pauvilai P, et al. 
Safety and antisorptive power of Ibandronate applied in the real-life setting. [Journal Article, Research Support, Non-U.S. Gov't]
J Med Assoc Thai 2009 Sep.:S72-5.
Abstract | Full CitationInfusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.http://www.unboundmedicine.com/medline/ebm/record/19855926/full_citation/Infusion_of_ibandronate_once_every_3_months_effectively_decreases_bone_resorption_markers_and_increases_bone_mineral_density_in_Chinese_postmenopausal_osteoporotic_women:_a_1_year_study_Li M, Xing XP, Zhang ZL, et al. 
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. [JOURNAL ARTICLE]
J Bone Miner Metab 2009 Oct 24.
Abstract | Full Citation | Find Related Articles Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.http://www.unboundmedicine.com/medline/ebm/record/19851511/full_citation/Gastrointestinal_tolerability_with_ibandronate_after_previous_weekly_bisphosphonate_treatment_Derman R, Kohles JD, Babbitt A 
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. [Journal Article]
Clin Interv Aging 2009.:357-65.
Abstract | Full Citation | Find Related Articles Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases.http://www.unboundmedicine.com/medline/ebm/record/19845802/full_citation/Osteoporosis_management:_a_perspective_based_on_bisphosphonate_data_from_randomised_clinical_trials_and_observational_databases_Boonen S, Kay R, Cooper C, et al. 
Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. [JOURNAL ARTICLE]
Int J Clin Pract 2009 Oct 20.
Abstract | Full Citation | Find Related Articles Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.http://www.unboundmedicine.com/medline/ebm/record/19835464/full_citation/Update_on_monthly_oral_bisphosphonate_therapy_for_the_treatment_of_osteoporosis:_focus_on_ibandronate_150_mg_and_risedronate_150_mg_Epstein S, Jeglitsch M, McCloskey E 
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. [JOURNAL ARTICLE]
Curr Med Res Opin 2009 Oct 16.
Abstract | Full Citation | Find Related Articles Pricey osteoporosis remedy doesn't beat older drugs.http://www.unboundmedicine.com/medline/ebm/record/19824126/full_citation/Pricey_osteoporosis_remedy_doesn't_beat_older_drugs_Pricey osteoporosis remedy doesn't beat older drugs. [Journal Article]
Consum Rep 2009 Aug; 74(8):19.
Full Citation | Find Related Articles [Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head]http://www.unboundmedicine.com/medline/ebm/record/19817207/full_citation/[Diagnosis_and_treatment_of_bone_marrow_edema_syndrome_of_the_hip_and_differential_diagnosis_from_avascular_necrosis_of_femoral_head]Li JF, Yan JY 
[Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head] [English Abstract, Journal Article]
Zhongguo Gu Shang 2009 Sep; 22(9):697-9.
Abstract | Full Citation | Find Related Articles Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women.http://www.unboundmedicine.com/medline/ebm/record/19816648/full_citation/Comparison_of_Monthly_Ibandronate_Versus_Weekly_Risedronate_in_Preference_Convenience_and_Bone_Turnover_Markers_in_Korean_Postmenopausal_Osteoporotic_Women_Chung YS, Lim SK, Chung HY, et al. 
Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women. [JOURNAL ARTICLE]
Calcif Tissue Int 2009 Oct 9.
Abstract | Full Citation | Find Related Articles Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw.http://www.unboundmedicine.com/medline/ebm/record/19805682/full_citation/Longitudinal_Cohort_Study_of_Risk_Factors_in_Cancer_Patients_of_Bisphosphonate_Related_Osteonecrosis_of_the_Jaw_Vahtsevanos K, Kyrgidis A, Verrou E, et al. 
Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw. [JOURNAL ARTICLE]
J Clin Oncol 2009 Oct 5.
Abstract | Full Citation | Find Related Articles Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.http://www.unboundmedicine.com/medline/ebm/record/19798459/full_citation/Predictors_of_oral_bisphosphonate_prescriptions_in_post_menopausal_women_with_osteoporosis_in_a_real_world_setting_in_the_USA_Asche C, Nelson R, McAdam-Marx C, et al. 
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. [JOURNAL ARTICLE]
Osteoporos Int 2009 Oct 2.
Abstract | Full Citation | Find Related Articles